Skip to main content
Signal8

Evofem Biosciences, Inc. (EVFM)

Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Evofem Biosciences, Inc. logo

Evofem Biosciences, Inc.

OTC:EVFMHealthcare
AH+0.00%$0.0043
Close$0.0043-28.93%
Mkt Cap$570K
EV-
Float132.53M
O/S132.53M
VOL2.7M sh
$ Vol$13K
RVOL24.51×
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Evofem Biosciences, Inc. logoOTC:EVFMAH$0.0043+0.00%
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›
  • AI analysis ›